Molecular and cellular stratagem of brain metastases associated with melanoma - PubMed (original) (raw)

Review

. 2019 May;17(5):4170-4175.

doi: 10.3892/ol.2019.9933. Epub 2019 Jan 14.

Affiliations

Review

Molecular and cellular stratagem of brain metastases associated with melanoma

Ana-Maria Buga et al. Oncol Lett. 2019 May.

Abstract

Tumors of the central nervous system are the most prevalent complications of melanoma, especially in the late stage of disease. Melanoma, lung and breast cancer are the leading cause of secondary tumors in the brain, the majority of them having a poor outcome. Brain dissemination is developed in half of stage IV melanomas and these cases can increase up to 75%, having a major impact on the quality of life. This review will focus on recent findings that provide new ways to potentially prevent brain metastases in malignant melanoma. The key of these findings is based on the heterogeneity of the melanoma and of the brain metastases at genetic levels. This new era of technologies provides new tools in understanding the dissemination mechanisms of malignant cells. The cellular and molecular changes, the immune status of the patient and the blood-brain barrier permeability are key regulators of cancer cell dissemination. Understanding these mechanisms can render new hope in preventing brain metastases by focusing on melanoma and new pharmacologic approaches.

Keywords: blood-brain barrier; brain metastases; immune status; melanoma.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Brain metastases: i) Need a protective environment; ii) promote vasculogenesis; and iii) neurovascular niche is crucial for tumor development and survival.

Figure 2.

Figure 2.

From 88 registered clinical trials, 22 studies were in phase 1; 51 studies in phase 2; 5 studies in phase 3; and only 2 studies in phase 4.

Similar articles

Cited by

References

    1. Nussbaum L, Hogea LM, Călina D, Andreescu N, Grădinaru L, Stefănescu R, Puiu M. Modern treatment approaches in psychoses. Pharmacogenetic, neuroimagistic and clinical implications. Farmacia. 2017;65:75–81.
    1. Neagu M, Caruntu C, Constantin C, Boda D, Zurac S, Spandidos DA, Tsatsakis AM. Chemically induced skin carcinogenesis: Updates in experimental models (Review) Oncol Rep. 2016;35:2516–2528. doi: 10.3892/or.2016.4683. - DOI - PMC - PubMed
    1. Gugger A, Barnhill RL, Seifert B, Dehler S, Moch H, Lugassy C, Marques-Maggio E, Rushing JE, Mihic-Probst D. Cutaneous melanoma with brain metastasis: Report of 193 patients with new observations. PLoS One. 2016;11:e0156115. doi: 10.1371/journal.pone.0156115. - DOI - PMC - PubMed
    1. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950–5956. doi: 10.1200/JCO.2008.16.1927. - DOI - PubMed
    1. Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Hölzel D, Coebergh JW, Engel J, Munich Melanoma Group Gender differences in melanoma survival: Female patients have a decreased risk of metastasis. J Invest Dermatol. 2011;131:719–726. doi: 10.1038/jid.2010.354. - DOI - PubMed

Publication types

LinkOut - more resources